Could less be more? major trial questions routine antibiotic for heart valve infections
NCT ID NCT07253688
First seen Jun 27, 2026 · Last updated Sep 21, 2026 · Updated 1 time
Summary
This study looks at 330 adults with a serious heart valve infection (prosthetic valve endocarditis) caused by S. aureus bacteria. It compares the standard approach of giving the antibiotic rifampin against not giving it, to see if skipping it is just as safe and effective. The goal is to reduce unnecessary side effects while still controlling the infection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
1 person
The number who actually took part.
- Started
-
Nov 2025
- Finished
-
Sep 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Probable or definite prosthetic valve endocarditis involving the tricuspid, pulmonic, mitral and/or aortic valves by the 2023 Duke-ISCVID Criteria (including Cardiac PET evidence if applicable); 2. Patient or healthcare proxy provide informed consent. Exclusion Criteria: 1. Death deemed imminent and inevitable within days or patient will be receiving palliative care and has prognosis \< 90 days according to the treating team; 2. Patient requires intensive care but has a do not resuscitate order precluding transfer; 3. Polymicrobial bacteremia (not including skin commensals or other recognized contaminant); 4. Organism tests as rifampin resistant; 5. History of hypersensitivity/anaphylaxis or severe adverse reaction to rifampin; 6. Category X or other important drug-drug interaction with rifampin which cannot be safely mitigated \[with as-needed consultation from experts from pharmacy and/or internal medicine/geriatrics for potential deprescribing\]; 7. Child Pugh Class C cirrhosis; 8. Clinician deems rifampin to be mandatory; 9. Patient has already received \>3 days of rifampin at time of screening or \>10 days of total therapy 10. Pregnancy or breast feeding Administrative exclusions: 1. No reliable means of outpatient contact (telephone/email/text); 2. Previously enrolled; 3. Prior S. aureus bacteremia within the preceding 180 days
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Prosthetic valve endocarditis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
Montreal, Quebec, H4A4S1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.